Athenex's gross profit for the
three
months ended in Dec. 2022 was $6.2 Mil. Athenex's gross profit for the trailing twelve months (TTM) ended in Dec. 2022 was $26.8 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Athenex's gross profit for the
three
months ended in Dec. 2022 was $6.2 Mil. Athenex's Revenue for the
three
months ended in Dec. 2022 was $8.6 Mil. Therefore, Athenex's Gross Margin % for the quarter that ended in Dec. 2022 was 71.49%.
Athenex had a gross margin of 71.49% for the quarter that ended in Dec. 2022 => Durable competitive advantage
Athenex Gross Profit Historical Data
The historical data trend for Athenex's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Athenex's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Athenex's Gross Profit Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Athenex's Gross Profit distribution charts can be found below:
* The bar in red indicates where Athenex's Gross Profit falls into.
Athenex Gross Profit Calculation
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
Athenex's Gross Profit for the fiscal year that ended in Dec. 2022 is calculated as
Gross Profit for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $26.8 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Athenex (OTCPK:ATNXQ) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Athenex had a gross margin of 71.49% for the quarter that ended in Dec. 2022 => Durable competitive advantage
Athenex Gross Profit Related Terms
Thank you for viewing the detailed overview of Athenex's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Its current clinical pipeline is derived from Orascovery, based on a P-glycoprotein (P-gp) pump inhibitor, Src Kinase inhibition, T-cell receptor-engineered T-cells, and arginine deprivation therapy technology platforms. It is primarily engaged in conducting research and development activities through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting preclinical and clinical testing, recruiting personnel, identifying and evaluating additional drug candidates for potential in-licensing or acquisition, and raising capital to support development and commercialization activities.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ATNXQ has been successfully added to your 